[go: up one dir, main page]

PT3551166T - Fenitoína tópica para utilização no tratamento de dor neuropática periférica - Google Patents

Fenitoína tópica para utilização no tratamento de dor neuropática periférica

Info

Publication number
PT3551166T
PT3551166T PT178179271T PT17817927T PT3551166T PT 3551166 T PT3551166 T PT 3551166T PT 178179271 T PT178179271 T PT 178179271T PT 17817927 T PT17817927 T PT 17817927T PT 3551166 T PT3551166 T PT 3551166T
Authority
PT
Portugal
Prior art keywords
treatment
neuropathic pain
peripheral neuropathic
phenytoin
topical
Prior art date
Application number
PT178179271T
Other languages
English (en)
Original Assignee
Topical Innovations B V
Keppel Hesselink Jan Marius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topical Innovations B V, Keppel Hesselink Jan Marius filed Critical Topical Innovations B V
Publication of PT3551166T publication Critical patent/PT3551166T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT178179271T 2016-12-06 2017-12-06 Fenitoína tópica para utilização no tratamento de dor neuropática periférica PT3551166T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2017931 2016-12-06

Publications (1)

Publication Number Publication Date
PT3551166T true PT3551166T (pt) 2024-10-28

Family

ID=57796933

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178179271T PT3551166T (pt) 2016-12-06 2017-12-06 Fenitoína tópica para utilização no tratamento de dor neuropática periférica

Country Status (21)

Country Link
US (1) US11285099B2 (pt)
EP (1) EP3551166B1 (pt)
JP (1) JP7264813B2 (pt)
CN (1) CN110248644A (pt)
AU (1) AU2017371467B2 (pt)
BR (1) BR112019011743A2 (pt)
CA (1) CA3046055A1 (pt)
CL (1) CL2019001550A1 (pt)
DK (1) DK3551166T3 (pt)
DO (1) DOP2019000156A (pt)
EA (1) EA201991341A1 (pt)
ES (1) ES2991885T3 (pt)
FI (1) FI3551166T3 (pt)
IL (1) IL267114B2 (pt)
MA (1) MA51978A (pt)
MX (1) MX2019006640A (pt)
PH (1) PH12019550093A1 (pt)
PT (1) PT3551166T (pt)
UA (1) UA125040C2 (pt)
WO (1) WO2018106107A1 (pt)
ZA (1) ZA201906473B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005034B2 (en) 2017-04-25 2024-06-11 Algotherapeutix Topical pharmaceutical composition comprising at least amitriptyline, for the treatment of peripheral neuropathic pain
FR3095589B1 (fr) * 2019-05-02 2021-05-07 Air Liquide Mélange gazeux inhalable pour traiter les douleurs chroniques chez des patients recevant des médicaments de plusieurs classes thérapeutiques
US12440469B2 (en) 2019-09-02 2025-10-14 Syddansk Universitet P-gp inducers as protectors against chemotherapy-induced side effects, such as peripheral neuropathy (CIPN) and hair loss
FR3108841B1 (fr) 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
CN114681340A (zh) * 2022-04-13 2022-07-01 肌赋萃生物科技(上海)有限公司 一种含有脂质包裹稳定技术的脂质屏障修复护肤品及其制备方法
WO2024120461A1 (zh) * 2022-12-09 2024-06-13 荣昌生物制药(烟台)股份有限公司 Cyp3a4/5诱导剂在治疗或缓解周围神经病变中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571521A (en) 1984-01-16 1996-11-05 Lasker; Sigmund E. Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
JP3031973B2 (ja) 1990-08-16 2000-04-10 富士レビオ株式会社 フェニトイン誘導体
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
CN1046199C (zh) * 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
WO1998007447A1 (en) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
AU5824800A (en) 1999-06-23 2001-01-31 Warner-Lambert Company Use of fosphenytoin for the treatment of acute neuropathic pain
US20040191276A1 (en) 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
CZ20033116A3 (cs) * 2001-05-15 2004-09-15 Warner-Lambert Company Llc Způsob výroby lékové formy fenytoinu sodného užívající kompaktor
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
NZ553024A (en) * 2004-08-03 2009-11-27 Royal College Of Surgeons Ie Phenytoin formulations, and uses thereof in wound healing
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
CN101069692B (zh) * 2006-05-08 2011-04-20 范敏华 含积雪草总甙的药物制剂及其制备方法
WO2008079727A2 (en) 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
EP2286828B1 (en) * 2008-04-14 2016-05-18 National University Corporation Nagoya University Improving agent for neuropathic pain
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ,エルエルシー 局所局部的神経作用療法
AU2009296457A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
KR101271219B1 (ko) * 2011-01-27 2013-06-07 광주과학기술원 신규한 하이단토인 유도체 및 이의 용도
KR101593339B1 (ko) 2011-06-20 2016-02-11 히사미쓰 세이야꾸 가부시키가이샤 리도카인 함유 파프제
US20130184351A1 (en) 2011-12-21 2013-07-18 Jar Laboratories Lidocaine patch and methods of use thereof
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
WO2015089050A1 (en) * 2013-12-09 2015-06-18 Malshe Research And Development, Llc Compositions and methods for the treatment of wounds
CN106075556A (zh) 2016-06-02 2016-11-09 四川奎星医用高分子制品有限责任公司 含有促进伤口愈合药物的医用复合壳聚糖凝胶

Also Published As

Publication number Publication date
IL267114B1 (en) 2024-04-01
UA125040C2 (uk) 2021-12-29
PH12019550093A1 (en) 2020-02-10
FI3551166T3 (fi) 2024-10-04
US11285099B2 (en) 2022-03-29
ZA201906473B (en) 2020-07-29
IL267114B2 (en) 2024-08-01
JP2020500915A (ja) 2020-01-16
CN110248644A (zh) 2019-09-17
CA3046055A1 (en) 2018-06-14
EP3551166B1 (en) 2024-08-21
IL267114A (en) 2019-08-29
DOP2019000156A (es) 2020-07-15
EP3551166A1 (en) 2019-10-16
CL2019001550A1 (es) 2020-02-28
ES2991885T3 (es) 2024-12-05
MX2019006640A (es) 2019-08-01
JP7264813B2 (ja) 2023-04-25
US20200276106A1 (en) 2020-09-03
AU2017371467A1 (en) 2019-07-25
EA201991341A1 (ru) 2019-12-30
MA51978A (fr) 2021-01-20
DK3551166T3 (da) 2024-10-21
AU2017371467B2 (en) 2023-06-01
BR112019011743A2 (pt) 2019-10-22
WO2018106107A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
IL290150A (en) Compounds and methods for treating chronic pain
ZA201906473B (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain
IL266198A (en) Liposomal formulation for use in cancer treatment
ZA201704726B (en) Peptides and their use in the treatment of skin
IL270978B (en) Grape skin for use in the treatment of dysbiosis
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
PT3423060T (pt) Imatinib para utilização no tratamento de acidente vascular cerebral
IL246855A0 (en) Materials for use in the treatment of retinitis
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
IL269894B (en) Small organic molecules for use in the treatment of neuroinflammatory diseases
GB2568132B (en) High-performance hair treatment agents with increased care effect
PL3621614T3 (pl) Lotion zawierający tazaroten do stosowania miejscowego w leczeniu trądziku
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL273863A (en) Hemorrhoid treatment device
IL269121A (en) Usl-311 for use in the treatment of cancer
GB201423268D0 (en) The combination for acne cleansing and skin metabolism improving
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
HK40015081B (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain
PL3478260T3 (pl) Kompozycja do pielęgnacji skóry i jej zastosowanie
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
HK40027056A (en) Grape skin for use in the treatment of dysbiosis
GB201718111D0 (en) Skin treatment device
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
HUE064521T2 (hu) Tamoxifen alkalmazása cisztás fibrózis kezelésére nem nõi pácienseknél